Technical Analysis for RVNC - Revance Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 16.32 2.00% 0.32
RVNC closed up 2.0 percent on Tuesday, March 19, 2019, on 64 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical RVNC trend table...

Date Alert Name Type % Chg
Mar 19 Slingshot Bearish Bearish Swing Setup 0.00%
Mar 19 Stochastic Buy Signal Bullish 0.00%
Mar 19 Oversold Stochastic Weakness 0.00%
Mar 18 Slingshot Bearish Bearish Swing Setup 2.00%
Mar 18 New 52 Week Low Weakness 2.00%
Mar 18 Outside Day Range Expansion 2.00%
Mar 18 Lower Bollinger Band Touch Weakness 2.00%
Mar 18 Oversold Stochastic Weakness 2.00%
Mar 15 New 52 Week Closing Low Bearish 5.63%
Mar 15 Narrow Range Bar Range Contraction 5.63%

Older signals for RVNC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.
Biopharmaceutical Pain Drugs Migraine Plastic Surgery Toxins Botulinum Toxin Botulism Hyperhidrosis Neurotoxins Prevention Of Migraine Rhinitis
Is RVNC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 34.2
52 Week Low 15.07
Average Volume 523,139
200-Day Moving Average 23.3093
50-Day Moving Average 17.4507
20-Day Moving Average 16.6205
10-Day Moving Average 16.027
Average True Range 0.6866
ADX 18.74
+DI 20.7003
-DI 24.0656
Chandelier Exit (Long, 3 ATRs ) 16.0902
Chandelier Exit (Short, 3 ATRs ) 17.1298
Upper Bollinger Band 17.9419
Lower Bollinger Band 15.2991
Percent B (%b) 0.39
BandWidth 15.900845
MACD Line -0.4833
MACD Signal Line -0.4739
MACD Histogram -0.0093
Fundamentals Value
Market Cap 502.97 Million
Num Shares 30.8 Million
EPS -3.44
Price-to-Earnings (P/E) Ratio -4.74
Price-to-Sales 2609.34
Price-to-Book 4.85
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.15
Resistance 3 (R3) 17.11 16.80 17.01
Resistance 2 (R2) 16.80 16.59 16.82 16.96
Resistance 1 (R1) 16.56 16.46 16.68 16.60 16.92
Pivot Point 16.25 16.25 16.31 16.27 16.25
Support 1 (S1) 16.01 16.04 16.13 16.04 15.72
Support 2 (S2) 15.70 15.91 15.71 15.68
Support 3 (S3) 15.46 15.70 15.63
Support 4 (S4) 15.49